Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04256577
Other study ID # serum ceramides level in (SLE)
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2020
Est. completion date June 2021

Study information

Verified date January 2020
Source Assiut University
Contact nadia hussien hammam, Resident doctor
Phone 01006912253
Email dr.nadia_hussien@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. Estimation of serum ceramides level in SLE patients as anovel marker for renal impairment

2. Correlation serum ceramides level with histological classification of LN,C3,C4,ANA,ANTI DS DNA ,CRP ,ESR , eGFR , creatinine /protein ratio

3. Follow up estimation of ceramides level in LN patients after 3 cycles of treatment


Description:

Systemic lupus erythrematosus (SLE) is an autoimmune disease with increasing prevalence and incidence , The clinical manifestation is multifaceted and targets the musculoskeletal system, the skin and different organs like lung and kidney From 30-80% of SLE patients develop lupus nephritis (LN) which often leads to chronic kidney disease (CKD) and end-stage renal disease (ESRD) and is associated with an overall poor prognosis and high mortality Diagnosis of LN is made by kidney biopsy, which still remains the gold standard Histological evaluation distinguish between different stages of LN upon morphological changes within the kidney . However, noninvasive methods to diagnose and guide LN therapy are currently not established in the clinic. On the other hand, an early diagnosis is important for the therapeutic success and thereby lowers the risk of ESRD In this context, classical clinical markers for renal dysfunction are insufficient for an early assessment of the need for renal biopsies and subsequently to decide about the optimal therapy. Even though traditional biomarkers like antids DNA antibodies and complement deficiency are widely accepted as diagnostic instruments to assess disease activity, their specificity is rather low, and they appear to be more suitable to confirm diagnosis of SLE and LN in an already likely clinical setting Ceramides are a family of waxy lipid molecules ,composed of sphingosine and fatty acide ,found in high concentration with in the cell membrane of eukaryocyte cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer Ceramides and other sphingolipids found in cell membrane were purely supporting structural elements,also participate in variety of cellular signaling, regulating differentiation, proliferation, Programmed cell death(PCD) Sphingolipids are a heterogenous group of lipids with more than 400 single compounds formed by structural and chemical modifications of a sphingosine backbone Recent studies reveal that blood sphingolipids not only have important signaling properties but also serve as biomarkers in various renal disease Patyna etal in 2019 concluded that ceramides in blood could act as potent biomarker for renal impairment in patient


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date June 2021
Est. primary completion date February 2021
Accepts healthy volunteers
Gender All
Age group 17 Years to 60 Years
Eligibility Inclusion Criteria:

- Forty five patients will SLE with and without renal impairment diagnosed as SLE according to SLICC classification criteria for SLE

Exclusion Criteria:

- Malignant tumor ,infectious diseases, Alzheimer disease ,type 2 diabetes mellitus vitamin D intaker, obesty , cardiovascular disease (HTN,HF ,ischemic heart disease)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
serum ceramides level in blood
Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Patyna S, Büttner S, Eckes T, Obermüller N, Bartel C, Braner A, Trautmann S, Thomas D, Geiger H, Pfeilschifter J, Koch A. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106348. doi: 10.1016/j.prostaglandins.2019.106348. Epub 2019 Jul 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Estimation of serum ceramides level in SLE patients as anovel marker for renal impairment Correlation serum ceramides level with histological classification of LN,C3,C4,ANA,ANTI DS DNA ,CRP ,ESR , eGFR , creatinine /protein ratio base line
See also
  Status Clinical Trial Phase
Completed NCT03749044 - ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies N/A
Completed NCT03218033 - Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus N/A
Not yet recruiting NCT03752983 - Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
Recruiting NCT03819777 - Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Recruiting NCT04894253 - Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
Not yet recruiting NCT03164720 - SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
Completed NCT03762824 - Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Phase 4
Not yet recruiting NCT06435468 - Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases N/A
Terminated NCT01738360 - Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) Phase 2
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT04108611 - Immune Adsorption Role in Treatment of Resistant Lupus N/A
Completed NCT03540823 - Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Phase 4